Skip to main content
Barinthus Biotherapeutics plc. logo

Barinthus Biotherapeutics plc. — Investor Relations & Filings

Ticker · BRNS ISIN · US91864C1071 LEI · 213800KQ9EAOKPWN8A33 US Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country GB United Kingdom
Listing US BRNS

About Barinthus Biotherapeutics plc.

https://www.barinthusbio.com/

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company that develops novel immunotherapies designed to guide T cells to control disease. The company is advancing a new generation of antigen-specific immunotherapeutics for treating autoimmunity, chronic infectious diseases, and cancer. Its therapeutic approach focuses on creating candidates that can overcome these conditions by modulating the body's T cell response. The development pipeline includes programs targeting various indications, with a strategic focus on immunology and inflammatory diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K “Current Report” filed under Exchange Act Section 13/15(d) describing Item 5.07 “Submission of Matters to a Vote of Security Holders,” including the final vote tallies and results at a Court Meeting and General Meeting. This clearly constitutes an official declaration of voting results at shareholder meetings. Therefore, it falls under Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 English
10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-30 English
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text includes an Item 2.02 section titled 'Results of Operations and Financial Condition' and mentions a press release with financial results for the quarter ended March 31, 2026. The document also references a registration statement on Form S-4 related to a proposed transaction, indicating merger-related activity. However, the primary content is the announcement of quarterly financial results via a press release attached as Exhibit 99.1. The document is not the full quarterly report itself but a current report announcing financial results. Therefore, it fits best under the category of Earnings Release (ER), which covers initial announcements of quarterly financial results. The document length (7049 characters) supports it being more than a brief notice but still an announcement rather than a full interim report. Hence, the classification is ER with high confidence.
2026-04-30 English
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new Chief Financial Officer and principal accounting officer, including biographical information and terms of engagement. This fits the description of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not a full financial report, earnings release, or other types of filings. Therefore, the correct classification is MANG.
2026-04-22 English
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
M&A Activity Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated February 23, 2026, by Barinthus Biotherapeutics plc. It details an amendment to a merger agreement and provides extensive information about the merger transaction, including the parties involved, the terms of the amendment, and references to related filings such as a registration statement and proxy statement. The document is focused on merger-related disclosures and updates on the transaction timeline and conditions. It is not a full annual or quarterly report, nor is it a proxy solicitation or voting results announcement. It is a current report disclosing a material definitive agreement amendment related to a merger, which fits the category of M&A Activity filings. The length (15,000 characters) and detailed content confirm it is a substantive filing rather than a brief announcement or certification. Therefore, the appropriate classification is M&A Activity (Code: TAR).
2026-02-23 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 30, 2025, by Barinthus Biotherapeutics plc. The key content is a notice from Nasdaq indicating the company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. The document discusses the receipt of a delisting notice and the company's plan to regain compliance, including the possibility of a reverse stock split. This is a formal announcement regarding the potential delisting of the company's stock from an exchange. Therefore, the document fits the category of a Delisting Announcement (DLST). The document length is 4752 characters, which is sufficient to be the actual announcement, not just a brief notice or report publication announcement. Hence, the classification is DLST with high confidence.
2026-01-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.